About our Pharmaceuticals news
Latest news on the pharmaceutical industry, covering drug development, clinical trials, FDA approvals, drug pricing, biotech M&A, and generic medicines.
The pharmaceutical industry spans the discovery, testing, manufacturing and distribution of medicines used by patients worldwide. Major companies, often called Big Pharma, work alongside smaller biotech firms, contract manufacturers and generic drugmakers to bring treatments from laboratory research through clinical trials to market approval. Regulators including the US Food and Drug Administration, the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency oversee safety and efficacy standards throughout this process.
Drug pricing remains one of the industry's most persistent points of tension, with governments and insurers pushing for lower costs while companies argue this could reduce funding for future research. Trade measures on pharmaceutical imports have added further pressure, prompting some manufacturers to reconsider global supply chains and expand domestic production. Patent expiries on blockbuster drugs, known as loss of exclusivity, continue to reshape company strategies, driving a wave of mergers, acquisitions and licensing deals as firms replenish their pipelines.
Beyond the boardroom, pharmaceutical developments touch everyday lives through the medicines people rely on for chronic conditions, infectious disease and rare disorders. GLP-1 drugs, originally developed for diabetes, have reshaped conversations around obesity treatment and sparked debate over access, affordability and misuse outside clinical supervision. Patient advocacy groups continue to push for equitable access to new therapies, particularly in lower-income regions where treatment costs can be prohibitive.
The industry traces its modern origins to the early twentieth century, when the mass production of antibiotics and vaccines transformed public health. Since then, it has evolved through waves of innovation, from small-molecule chemistry to biologics, and more recently to gene therapy and mRNA-based medicines. Artificial intelligence is now accelerating drug discovery and clinical trial design, helping researchers identify promising compounds and predict how they interact with the human body.
Generic and biosimilar medicines play a growing role in expanding access once patents expire, offering more affordable alternatives without compromising safety standards. Meanwhile, counterfeit and unregulated medicines remain a global concern, particularly as demand for popular treatments outpaces legitimate supply in some markets. Ongoing efforts by regulators and manufacturers aim to strengthen supply chain security and protect patients from substandard products.
Stay informed with our NewsNow feed on the pharmaceutical industry, bringing together the latest headlines on drug approvals, pricing debates, clinical breakthroughs and corporate dealmaking from trusted sources around the world.
